Alan D T Barrett

List of Publications by Citations

183 papers	7,305 citations	48 h-index	79 g-index
200 ext. papers	8,274 ext. citations	7.6 avg, IF	6.28 L-index

#	Paper	IF	Citations
183	Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. *Journal of Virology*, **2000**, 74, 3227-34	6.6	282
182	Yellow fever: a disease that has yet to be conquered. *Annual Review of Entomology*, **2007**, 52, 209-29	21.8	250
181	Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. *Journal of Virology*, **2005**, 79, 8339-47	6.6	250
180	Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. *Viral Immunology*, **2008**, 21, 123-32	1.7	246
179	Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. *Journal of Virology*, **2002**, 76, 13097-100	6.6	215
178	Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. *Virology*, **2002**, 296, 17-23	3.6	209
177	Phylogenetic analysis of North American West Nile virus isolates, 2001-2004: evidence for the emergence of a dominant genotype. *Virology*, **2005**, 342, 252-65	3.6	195
176	Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. *PLoS Pathogens*, **2007**, 3, e75	7.6	190
175	West Nile virus: where are we now?. *Lancet Infectious Diseases, The*, **2004**, 4, 547-56	25.5	187
174	Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas. *Journal of Virology*, **2011**, 85, 2964-74	6.6	174
173	Flavivirus-induced antibody cross-reactivity. *Journal of General Virology*, **2011**, 92, 2821-2829	4.9	163
172	Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. *Virology*, **2007**, 366, 349-60	3.6	151
171	Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. *Current Opinion in Immunology*, **2009**, 21, 308-13	7.8	130
170	Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. *Journal of Virology*, **2008**, 82, 8828-37	6.6	127
169	West Nile virus in Mexico: evidence of widespread circulation since July 2002. *Emerging Infectious Diseases*, **2003**, 9, 1604-7	10.2	120
168	Genetic variation in the 3′ non-coding region of dengue viruses. *Virology*, **2001**, 281, 75-87	3.6	100
167	Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. *Journal of Neuroscience*, **2015**, 35, 4857-68	6.6	99

166	Limited evolution of West Nile virus has occurred during its southwesterly spread in the United States. *Virology*, **2003**, 309, 190-5	3.6	99
165	A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. *Virology*, **2006**, 349, 245-53	3.6	86
164	Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. *Journal of Virology*, **2001**, 75, 6999-7008	6.6	85
163	Emergence of attenuated West Nile virus variants in Texas, 2003. *Virology*, **2004**, 330, 342-50	3.6	83
162	Genetic variation in yellow fever virus: duplication in the 3Rnoncoding region of strains from Africa. *Virology*, **1996**, 225, 274-81	3.6	81
161	Vector- and Rodent-borne Diseases in Europe and North America: Distribution, Public Health Burden and Control. *Emerging Infectious Diseases*, **2007**, 13, 1278-1278	10.2	78
160	Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. *Lancet Infectious Diseases, The*, **2019**, 19, e31-e38	25.5	76
159	Genetic divergence and dispersal of yellow fever virus, Brazil. *Emerging Infectious Diseases*, **2004**, 10, 1578-84	10.2	75
158	Phylogeography of Japanese encephalitis virus: genotype is associated with climate. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2411	4.8	73
157	Yellow fever vaccines. *Biologicals*, **1997**, 25, 17-25	1.8	70
156	Phylogeny of the Simbu serogroup of the genus Bunyavirus. *Journal of General Virology*, **2001**, 82, 2173-2181	4.8	68
155	Yellow Fever in Angola and Beyond--The Problem of Vaccine Supply and Demand. *New England Journal of Medicine*, **2016**, 375, 301-3	59.2	67
154	Gamma delta T cells facilitate adaptive immunity against West Nile virus infection in mice. *Journal of Immunology*, **2006**, 177, 1825-32	5.3	67
153	The enigma of yellow fever in East Africa. *Reviews in Medical Virology*, **2008**, 18, 331-46	11.7	65
152	Evolution of new genotype of West Nile virus in North America. *Emerging Infectious Diseases*, **2011**, 17, 785-93	10.2	64
151	Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day. *Current Infectious Disease Reports*, **2017**, 19, 14	3.9	62
150	Genome sequence and attenuating mutations in West Nile virus isolate from Mexico. *Emerging Infectious Diseases*, **2004**, 10, 2221-4	10.2	62
149	Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants. *Virology*, **1998**, 241, 30-6	3.6	61

148	Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. *Journal of Infectious Diseases*, **2004**, 189, 669-76	7	61
147	Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. *Vaccine*, **2004**, 22, 3722-6	4.1	61
146	Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation. *Npj Vaccines*, **2018**, 3, 24	9.5	60
145	A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. *Journal of Virology*, **2015**, 89, 1254-66	6.6	59
144	Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. *Vaccine*, **2010**, 28, 1075-83	4.1	59
143	Introductions of West Nile virus strains to Mexico. *Emerging Infectious Diseases*, **2006**, 12, 314-8	10.2	58
142	Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. *Journal of Infectious Diseases*, **2014**, 209, 334-44	7	54
141	Current status of flavivirus vaccines. *Annals of the New York Academy of Sciences*, **2001**, 951, 262-71	6.5	54
140	Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection. *Journal of Clinical Microbiology*, **2004**, 42, 2759-65	9.7	54
139	Genetic variation among temporally and geographically distinct West Nile virus isolates, United States, 2001, 2002. *Emerging Infectious Diseases*, **2003**, 9, 1423-9	10.2	53
138	Nucleotide sequences and phylogeny of the nucleocapsid gene of Oropouche virus. *Journal of General Virology*, **2000**, 81, 743-8	4.9	53
137	Molecular evolution of lineage 2 West Nile virus. *Journal of General Virology*, **2013**, 94, 318-325	4.9	50
136	Jatobal virus is a reassortant containing the small RNA of Oropouche virus. *Virus Research*, **2001**, 77, 25-30	3.4	49
135	Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease. *Vaccine*, **2017**, 35, 5951-5955	4.1	47
134	Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. *Npj Vaccines*, **2018**, 3, 11	9.5	47
133	Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. *Virology*, **1998**, 244, 59-65	3.6	47
132	West Nile Virus isolation in human and mosquitoes, Mexico. *Emerging Infectious Diseases*, **2005**, 11, 1449-52	10.2	47
131	Current status and future prospects of yellow fever vaccines. *Expert Review of Vaccines*, **2015**, 14, 1479-92	5.2	43

130	Tau oligomers mediate □synuclein toxicity and can be targeted by immunotherapy. *Molecular Neurodegeneration*, **2018**, 13, 13	19	43
129	Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. *Virology*, **2009**, 384, 16-20	3.6	43
128	Fast-Track Zika Vaccine Development - Is It Possible?. *New England Journal of Medicine*, **2016**, 375, 1212-6	59.2	42
127	Mutational analysis of the West Nile virus NS4B protein. *Virology*, **2012**, 426, 22-33	3.6	40
126	Molecular epidemiology and evolution of West Nile virus in North America. *International Journal of Environmental Research and Public Health*, **2013**, 10, 5111-29	4.6	39
125	Molecular characterization of a hamster viscerotropic strain of yellow fever virus. *Journal of Virology*, **2003**, 77, 1462-8	6.6	39
124	Mouse models of dengue virus infection for vaccine testing. *Vaccine*, **2015**, 33, 7051-60	4.1	38
123	The reemergence of yellow fever. *Science*, **2018**, 361, 847-848	33.3	38
122	Japanese encephalitis and dengue vaccines. *Biologicals*, **1997**, 25, 27-34	1.8	37
121	A mutation in the envelope protein fusion loop attenuates mouse neuroinvasiveness of the NY99 strain of West Nile virus. *Virology*, **2006**, 353, 35-40	3.6	36
120	Natural and nosocomial infection in a patient with West Nile encephalitis and extrapyramidal movement disorders. *Clinical Infectious Diseases*, **2003**, 36, E140-5	11.6	36
119	A Dengue Virus Type 4 Model of Disseminated Lethal Infection in AG129 Mice. *PLoS ONE*, **2015**, 10, e0125476	3.7	36
118	Multiple amino acid changes at the first glycosylation motif in NS1 protein of West Nile virus are necessary for complete attenuation for mouse neuroinvasiveness. *Vaccine*, **2011**, 29, 9702-10	4.1	34
117	Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. *Virology*, **2010**, 407, 237-46	3.6	34
116	Yellow fever vaccine **2013**, 870-968		33
115	Continued evolution of West Nile virus, Houston, Texas, USA, 2002-2012. *Emerging Infectious Diseases*, **2013**, 19, 1418-27	10.2	32
114	Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. *Virology*, **1999**, 261, 309-18	3.6	32
113	Genetic diversity of Japanese encephalitis virus isolates obtained from the Indonesian archipelago between 1974 and 1987. *Vector-Borne and Zoonotic Diseases*, **2013**, 13, 479-88	2.4	31

112	Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. *Vaccine*, **2006**, 24, 2803-9	4.1	31
111	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. *PLoS ONE*, **2021**, 16, e0253487	3.7	31
110	Twenty Years of Progress Toward West Nile Virus Vaccine Development. *Viruses*, **2019**, 11,	6.2	30
109	Evidence for co-evolution of West Nile Virus and house sparrows in North America. *PLoS Neglected Tropical Diseases*, **2014**, 8, e3262	4.8	30
108	Structure of yellow fever virus envelope protein domain III. *Virology*, **2009**, 394, 12-8	3.6	30
107	Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations. *Virus Research*, **1998**, 55, 93-9	6.4	30
106	Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. *Virology*, **1997**, 230, 376-80	3.6	29
105	Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections. *Journal of General Virology*, **2007**, 88, 981-990	4.9	29
104	A combination of naturally occurring mutations in North American West Nile virus nonstructural protein genes and in the 3′ untranslated region alters virus phenotype. *Journal of Virology*, **2007**, 81, 6111-6	6.6	29
103	Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. *MMWR Recommendations and Reports*, **2019**, 68, 1-33	37.3	29
102	West Nile in Europe: an increasing public health problem. *Journal of Travel Medicine*, **2018**, 25,	12.9	29
101	Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area. *Vaccine*, **1992**, 10, 861-72	4.1	28
100	Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants. *Journal of Virology*, **2000**, 74, 2903-6	6.6	27
99	Differential Infectivities among Different Japanese Encephalitis Virus Genotypes in Culex quinquefasciatus Mosquitoes. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0005038	4.8	27
98	Genetic variation of St. Louis encephalitis virus. *Journal of General Virology*, **2008**, 89, 1901-1910	4.9	26
97	Transstadial Transmission and Long-term Association of Crimean-Congo Hemorrhagic Fever Virus in Ticks Shapes Genome Plasticity. *Scientific Reports*, **2016**, 6, 35819	4.9	25
96	Reduced avian virulence and viremia of West Nile virus isolates from Mexico and Texas. *American Journal of Tropical Medicine and Hygiene*, **2011**, 85, 758-67	3.2	25
95	West Nile virus strains differ in mouse neurovirulence and binding to mouse or human brain membrane receptor preparations. *Annals of the New York Academy of Sciences*, **2001**, 951, 332-5	6.5	25

94	Genome analysis and phylogenetic relationships between east, central and west African isolates of Yellow fever virus. *Journal of General Virology*, **2006**, 87, 895-907	4.9	24
93	Current status of Severe Fever with Thrombocytopenia Syndrome vaccine development. *Current Opinion in Virology*, **2018**, 29, 72-78	7.5	21
92	Characterization of a murine model of non-lethal, symptomatic dengue virus infection. *Scientific Reports*, **2018**, 8, 4900	4.9	21
91	Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. *Vaccine*, **2014**, 32, 6537-43	4.1	21
90	Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into east and west Africa. *PLoS Neglected Tropical Diseases*, **2013**, 7, e1910	4.8	20
89	Characterization of lethal dengue virus type 4 (DENV-4) TVP-376 infection in mice lacking both IFN-/ and IFN- receptors (AG129) and comparison with the DENV-2 AG129 mouse model. *Journal of General Virology*, **2015**, 96, 3035-3048	4.9	20
88	A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity. *American Journal of Tropical Medicine and Hygiene*, **2013**, 88, 172-7	3.2	19
87	Genomic Characterization of Crimean-Congo Hemorrhagic Fever Virus in Hyalomma Tick from Spain, 2014. *Vector-Borne and Zoonotic Diseases*, **2017**, 17, 714-719	2.4	18
86	Molecular determinants of antigenicity of two subtypes of the tick-borne flavivirus Omsk haemorrhagic fever virus. *Journal of General Virology*, **2004**, 85, 1619-1624	4.9	17
85	Comparison of Oral Infectious Dose of West Nile Virus Isolates Representing Three Distinct Genotypes in Culex quinquefasciatus. *American Journal of Tropical Medicine and Hygiene*, **2008**, 79, 951-954	3.2	17
84	A lethal model of disseminated dengue virus type 1 infection in AG129 mice. *Journal of General Virology*, **2017**, 98, 2507-2519	4.9	17
83	Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. *Npj Vaccines*, **2020**, 5, 54	9.5	17
82	Structural and Nonstructural Genes Contribute to the Genetic Diversity of RNA Viruses. *MBio*, **2018**, 9,	7.8	17
81	The co-stimulatory effects of MyD88-dependent Toll-like receptor signaling on activation of murine T cells. *PLoS ONE*, **2014**, 9, e108156	3.7	16
80	Envelope and pre-membrane protein structural amino acid mutations mediate diminished avian growth and virulence of a Mexican West Nile virus isolate. *Journal of General Virology*, **2011**, 92, 2810-2820	4.9	16
79	Long range communication in the envelope protein domain III and its effect on the resistance of West Nile virus to antibody-mediated neutralization. *Journal of Biological Chemistry*, **2008**, 283, 613-622	5.4	15
78	Dynamic transmission of West Nile virus across the United States-Mexican border. *Virology*, **2013**, 436, 75-80	3.6	14
77	Amino acid substitution(s) in the stem-anchor region of langat virus envelope protein attenuates mouse neurovirulence. *Virology*, **2001**, 286, 54-61	3.6	14

76	Short report: comparison of oral infectious dose of West Nile virus isolates representing three distinct genotypes in Culex quinquefasciatus. *American Journal of Tropical Medicine and Hygiene*, **2008**, 79, 951-4	3.2	14
75	Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues. *Journal of General Virology*, **2015**, 96, 288-293	4.9	13
74	A West Nile virus NS4B-P38G mutant strain induces adaptive immunity via TLR7-MyD88-dependent and independent signaling pathways. *Vaccine*, **2013**, 31, 4143-51	4.1	13
73	Multiple pathways to the attenuation of West Nile virus in south-east Texas in 2003. *Virology*, **2010**, 405, 8-14	3.6	13
72	Characterization of a West Nile virus isolate from a human on the Gulf Coast of Texas. *Journal of Clinical Microbiology*, **2004**, 42, 5375-7	9.7	13
71	Analysis By Deep Sequencing of Discontinued Neurotropic Yellow Fever Vaccine Strains. *Scientific Reports*, **2018**, 8, 13408	4.9	13
70	The French neurotropic vaccine strain of yellow fever virus accumulates mutations slowly during passage in cell culture. *Virus Research*, **2000**, 69, 31-9	6.4	12
69	Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex. *MBio*, **2019**, 10,	7.8	11
68	Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes. *Virology*, **2012**, 422, 386-92	3.6	11
67	Detection and quantification of Epstein-Barr virus EBER1 in EBV-infected cells by fluorescent in situ hybridization and flow cytometry. *Journal of Virological Methods*, **1998**, 75, 83-91	2.6	11
66	Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008. *Antiviral Research*, **2018**, 154, 104-109	10.8	10
65	Characterization of Epstein-Barr virus reactivation in a modeled spaceflight system. *Journal of Cellular Biochemistry*, **2013**, 114, 616-24	4.7	10
64	Attenuated West Nile virus mutant NS1130-132QQA/175A/207A exhibits virus-induced ultrastructural changes and accumulation of protein in the endoplasmic reticulum. *Journal of Virology*, **2015**, 89, 1474-8	6.6	10
63	Flavivirus NS1 and Its Potential in Vaccine Development. *Vaccines*, **2021**, 9,	5.3	10
62	Phenotypic and molecular characterization of a non-lethal, hamster-viscerotropic strain of yellow fever virus. *Virus Research*, **2005**, 110, 65-71	6.4	9
61	Diagnosis of Oropouche virus infection using a recombinant nucleocapsid protein-based enzyme immunoassay. *Journal of Clinical Microbiology*, **2001**, 39, 2445-52	9.7	9
60	Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development. *Npj Vaccines*, **2020**, 5, 111	9.5	9
59	Virulence determinants of West Nile virus: how can these be used for vaccine design?. *Future Virology*, **2017**, 12, 283-295	2.4	8

58	Assessing the need for and acceptability of a free-of-charge postpartum HPV vaccination program. *American Journal of Obstetrics and Gynecology*, **2014**, 210, 213.e1-7	6.4	8
57	Comparative pathogenesis and systems biology for biodefense virus vaccine development. *Journal of Biomedicine and Biotechnology*, **2010**, 2010, 236528		8
56	Development pathway for biodefense vaccines. *Vaccine*, **2009**, 27 Suppl 4, D2-7	4.1	8
55	Yellow Fever Vaccines **2018**, 1181-1265.e20		7
54	Attenuation of Zika Virus by Passage in Human HeLa Cells. *Vaccines*, **2019**, 7,	5.3	7
53	Thermodynamic mechanism for the evasion of antibody neutralization in flaviviruses. *Journal of the American Chemical Society*, **2014**, 136, 10315-24	16.4	7
52	Vertebrate attenuated West Nile virus mutants have differing effects on vector competence in Culex tarsalis mosquitoes. *Journal of General Virology*, **2013**, 94, 1069-1072	4.9	7
51	An attenuated Zika virus NS4B protein mutant is a potent inducer of antiviral immune responses. *Npj Vaccines*, **2019**, 4, 48	9.5	7
50	Peli1 signaling blockade attenuates congenital zika syndrome. *PLoS Pathogens*, **2020**, 16, e1008538	7.6	6
49	Flaviviruses (Yellow Fever, Dengue, Dengue Hemorrhagic Fever, Japanese Encephalitis, West Nile Encephalitis, St. Louis Encephalitis, Tick-Borne Encephalitis) **2010**, 2133-2156		6
48	Yellow Fever Vaccine: The Conundrum of 2 Doses, One Dose, or One-Fifth Dose to Induce and Maintain Protective Immunity. *Journal of Infectious Diseases*, **2020**, 221, 1922-1924	7	6
47	Genotypic and phenotypic characterization of West Nile virus NS5 methyltransferase mutants. *Vaccine*, **2019**, 37, 7155-7164	4.1	5
46	Current status of the Arilvax; yellow fever vaccine. *Expert Review of Vaccines*, **2004**, 3, 413-20	5.2	5
45	Invasion Dynamics of Teratogenic Infections in Light of Rubella Control: Implications for Zika Virus. *PLOS Currents*, **2016**, 8,		5
44	Structure-Function of the Yellow Fever Virus Envelope Protein: Analysis of Antibody Epitopes. *Viral Immunology*, **2020**, 33, 12-21	1.7	5
43	Developing Zika vaccines: the lessons for disease X. *Genome Medicine*, **2018**, 10, 47	14.4	5
42	New vaccine development for chronic brain disease. *Neuropsychopharmacology*, **2010**, 35, 354	8.7	4
41	The Infectious Agent. *Tropical Medicine*, **2008**, 29-73		4

40	Langat virus M protein is structurally homologous to prM. *Journal of Virology*, **2001**, 75, 3999-4001	6.6	4
39	International laboratory network for yellow fever vaccine-associated adverse events. *Vaccine*, **2008**, 26, 5441-2	4.1	3
38	Japanese encephalitis vaccine-specific envelope protein E138K mutation does not attenuate virulence of West Nile virus. *Npj Vaccines*, **2019**, 4, 50	9.5	3
37	Adjuvants: Making Vaccines Immunogenic **2014**, 93-108		2
36	Political, Ethical, Social, and Psychological Aspects of Vaccinology **2014**, 335-357		2
35	1H, 13C and 15N resonance assignments for domain III of the West Nile virus envelope protein. *Journal of Biomolecular NMR*, **2004**, 29, 445-6	3	2
34	A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3. *Journal of General Virology*, **2017**, 98, 1299-1304	4.9	2
33	Zika vaccine pre-clinical and clinical data review with perspectives on the future development. *Human Vaccines and Immunotherapeutics*, **2020**, 16, 2524-2536	4.4	2
32	Long-Term Protection After Fractional-Dose Yellow Fever Vaccination. *Annals of Internal Medicine*, **2019**, 171, 145-146	8	2
31	Using Next Generation Sequencing to Study the Genetic Diversity of Candidate Live Attenuated Zika Vaccines. *Vaccines*, **2020**, 8,	5.3	2
30	A genetically stable Zika virus vaccine candidate protects mice against virus infection and vertical transmission. *Npj Vaccines*, **2021**, 6, 27	9.5	2
29	Japanese encephalitis virus live attenuated vaccine strains display altered immunogenicity, virulence and genetic diversity. *Npj Vaccines*, **2021**, 6, 112	9.5	2
28	Virulence of West Nile Virus in Different Animal Hosts **2009**, 137-153		2
27	The regulatory Path to Vaccine Licensure **2014**, 212-231		1
26	Flavivirus Infections in Humans **2013**,		1
25	The vaccine Development Pathway **2014**, 33-42		1
24	Arilvax (PowderJect). *Current Opinion in Investigational Drugs*, **2002**, 3, 992-5		1
23	Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development.. *Npj Vaccines*, **2022**, 7, 38	9.5	1

22	Impact of yellow fever virus envelope protein on wild-type and vaccine epitopes and tissue tropism.. *Npj Vaccines*, **2022**, 7, 39	9.5	1
21	Pathogenesis of Infectious Diseases and Mechanisms of Immunity **2014**, 59-72		0
20	Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies. *Npj Vaccines*, **2021**, 6, 139	9.5	0
19	Molecular Characterization of Hamster-Adapted Yellow Fever Virus. *Vector-Borne and Zoonotic Diseases*, **2020**, 20, 222-227	2.4	0
18	Understanding and Measuring the Dynamics of Infectious Disease Transmission **2014**, 304-318		
17	Veterinary Vaccines: Regulations and Impact on Emerging Infectious Diseases **2014**, 232-242		
16	Clinical Evaluation of Vaccines **2014**, 260-272		
15	Veterinary Vaccines **2014**, 181-191		
14	Development of Vaccines for Microbial Diseases **2014**, 192-211		
13	Discovery and the Basic Science Phase of Vaccine Development **2014**, 109-126		
12	Microbial-Based and Material-Based Vaccine Delivery Systems **2014**, 127-151		
11	Control and Eradication of Human and Animal Diseases by Vaccination **2014**, 43-58		
10	The History of Vaccine Development and the Diseases Vaccines Prevent **2014**, 1-32		
9	The Host Immune Response, Protective Immunity, and Correlates of Protection **2014**, 73-92		
8	Vaccine Recommendations and Special Populations **2014**, 273-286		
7	O4-06-01: Specific clearance of tau oligomers by passive immunization **2012**, 8, P624-P625		
6	West Nile Virus Isolation in Human and Mosquitoes, Mexico. *Emerging Infectious Diseases*, **2005**, 12, 1449-1452	10.5	
5	Finding Their Type: Elusive Antigenic Sites on Dengue Virus 3 Mapped with Human Antibodies. *Cell Host and Microbe*, **2020**, 27, 681-682	23.4	

4 Recent Expansion of Mosquito-Borne Pathogens Into Texas **2020**, 339-358

3 Arthropod-Borne Flaviviruses1267-1311

2 O5-06-05: Altering The Trajectory of Synucleinopathies by Targeting Downstream Toxicity of TAU Oligomers **2016**, 12, P391-P392

1 Yellow Fever Virus (Flaviviridae) **2021**, 891-898